Glenmark Pharmaceuticals Limited

NSE-GLENMARK
National Stock Exchange of India
Healthcare Drug Manufacturers - Specialty & Generic
Global Rank
#3051
Country Rank
#182
Market Cap
6.15 B
Price
21.8
Change (%)
0.33%
Volume
596,516

Glenmark Pharmaceuticals Limited (NSE-GLENMARK) Stock Split History

Date Split Ratio Multiple Cumulative multiple Type
09/10/2007 2:1 x2 x100 Forward
03/04/2005 2:1 x2 x50 Forward
10/25/2003 5:1 x5 x25 Forward
10/23/2003 5:1 x5 x5 Forward

Frequently Asked Questions

  • How much would Glenmark Pharmaceuticals Limited stock be worth if it never split?
    If Glenmark Pharmaceuticals Limited (stock symbol: NSE-GLENMARK) had never undergone any stock splits, its price per share today would be approximately 2179.51 USD. This calculation reflects the cumulative effect of all splits, including the most recent split (ratio: 2-for-1) that occurred on 09/10/2007.
  • Glenmark Pharmaceuticals Limited (stock symbol: NSE-GLENMARK) has undergone a total of four stock splits. The most recent split occurred on 09/10/2007. One share bought prior to the first split on 10/23/2003 would now equal 100.00 shares.
  • Glenmark Pharmaceuticals Limited (stock symbol: NSE-GLENMARK) has undergone four stock splits in its history. The most recent split, a 5-for-1 split, occurred on 09/10/2007. While future splits are not guaranteed, significant increases in stock price could prompt consideration for another split.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Ranking

Copyright © 2025. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.